ReviewWorld journal of gastroenterology2011
Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.
Review in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 98 citations in OpenAlex.
- HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Frontiers in immunology · 2026Review
- Hepatitis C virus-related hepatitis flare after immunochemotherapy in a patient with follicular lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness.Clinical journal of gastroenterology · 2024Article
- Case report: Recombinant human type II tumour necrosis factor receptor-antibody fusion protein induced occult hepatitis B virus reactivation leading to liver failure.The Journal of international medical research · 2024Article
- Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant.ACG case reports journal · 2024Article
- Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.Journal of personalized medicine · 2021Review
- Frequency of Hepatitis B Virus infection among Patients before Chemotherapy Treatment.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia.Clinical journal of gastroenterology · 2021Article
- Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.World journal of gastroenterology · 2021Review
- Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro.Virology journal · 2020Article
- Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015.Journal of clinical medicine · 2018Article
- Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians.Clinical medicine (London, England) · 2018Review
- Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.BMC gastroenterology · 2018Article
- Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.International urology and nephrology · 2017Article
- Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.Journal of cutaneous medicine and surgery · 2016Review
- Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.World journal of hepatology · 2016Review
- Long-Term Outcomes of Simultaneous Liver-Kidney Transplant Patients with Hepatitis B Compared to with Liver Transplant Alone.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study).European journal of rheumatology · 2015Article
- Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors.Digestive diseases and sciences · 2015Article
- Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactivation of hepatitis B is defined as the recurrence or an abrupt rise in hepatitis B virus (HBV) replication, often accompanied by an increase in serum transaminase levels, and both events occurring in a patient with a previous inactive hepatitis B infection. This reactivation can occur in situations in which the ratio of HBV replication and immune response is altered. It can happen during the treatment of hemato-oncological malignancies with chemotherapy and in immunosuppression of autoimmune diseases. Clinical manifestations of hepatitis B reactivation are variable and can range from asymptomatic to acute hepatitis, which are sometimes serious and result in acute liver failure with risk of death, and usually occur in the periods between cycles or at the end of chemotherapy. Immunosuppressive drugs such as corticosteroids or azathioprine can induce HBV reactivation in patients carrying hepatitis B virus surface antigen (HBsAg) or anti-HBc, but much less frequently than chemotherapy treatments. The tumor necrosis factor α inhibitors infliximab, etanercept and adalimumab may cause reactivation of hepatitis B, and the overall frequency with infliximab may be similar (50%-66%) to that caused by chemotherapy. Baseline HBV serology is recommended for all patients receiving chemotherapy and immunosuppressive drugs, and HBsAg positive patients should receive anti-HBV prophylaxis to decrease virus reactivation and death rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.